July 31 (Reuters) – AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
UK finance minister says FIFA's World Cup sale plan is collapsing
VIDEO SHOWS: BRITAIN'S FINANCE MINISTER JOHN HEALEY SPEAKING ABOUT FIFA'S PLANS TO SELL A STAKE…
UPDATE 2-Apple tumbles as supply chain snarls mar forecast in Cook's last earnings as CEO
(Updates share movement in paragraphs 1 and 2) By Aditya Soni and Rashika Singh July…
Veon raises outlook, flags digital investments in Ukraine
By Gianluca Lo Nostro July 31 (Reuters) - Veon, the parent company of Ukraine's leading…
